Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics)

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameAnti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics)
Drug Alias NameCD19 specific CART cellsAnti-CD19 CART cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsCentral Nervous System LymphomaNeuromyelitis OpticaMyasthenia Gravis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInnovative Cellular Therapeutics Co LtdKunming Medical UniversityZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of MedicineInnovative Cellular Therapeutics Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaNeuromyelitis OpticaMyasthenia Gravis +[6] 
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A